PDCD4-AS1: A Potential Drug Target and Biomarker (G282997)

Target Name: PDCD4-AS1

NCBI ID: G282997

PDCD4-AS1

Other Name(s): PDCD4 antisense RNA 1

PDCD4-AS1: A Potential Drug Target and Biomarker

PDCD4-AS1, also known as PDCD4 Antisense RNA 1, is a non-coding RNA molecule that has been identified as a potential drug target and biomarker for various diseases, including cancer. PDCD4-AS1 is expressed in most tissues and cells, and its levels are regulated by post-transcriptional modification and degradation processes. It is upregulated in a variety of cancers and is closely related to the progression and treatment response of many cancers.

PDCD4-AS1 is a 22nt RNA molecule consisting of an open reading frame (ORF) and an N-terminal tail. ORF includes a protein-coding gene region and an N-terminal non-coding RNA region. The N-terminal noncoding RNA region contains a conserved element consisting of GAGC repeat units found in genes whose expression is upregulated in a variety of cancers.

Expression of PDCD4-AS1 in various cancers

PDCD4-AS1 expression is up-regulated in a variety of cancers, including lung cancer, breast cancer, prostate cancer, and colon cancer. Studies have shown that the expression level of PDCD4-AS1 is closely related to cancer progression and treatment response. Cancer patients with upregulated expression of PDCD4-AS1 usually have poor prognosis, rapid disease progression, and poor response to traditional treatment options.

Pharmacological properties of PDCD4-AS1

PDCD4-AS1 is of high value in drug screening and drug research. First, PDCD4-AS1 can be used for drug target screening. Because PDCD4-AS1 is upregulated in a variety of cancers, it is a potential drug target. In addition, the expression level of PDCD4-AS1 can be used as a biomarker of tumor treatment response.

Clinical application of PDCD4-AS1

As a new biomarker, PDCD4-AS1 has great potential in clinical application in tumor patients. PDCD4-AS1 can be used as a monitoring indicator of tumor treatment response. It can be detected through blood samples to predict the treatment effect of tumor patients. In addition, PDCD4-AS1 can also be used as a predictor of tumor progression. Through the detection of tumor tissue samples, the progression of tumor patients can be predicted.

Biochemical properties of PDCD4-AS1

The biochemical properties of PDCD4-AS1 indicate that it has a high expression level and stability. PDCD4-AS1 can be expressed in a variety of tissue cells, including liver cells, kidney cells, and embryonic cells. In addition, PDCD4-AS1 has good stability in vitro and can be stored for long periods of time and maintain activity after repeated freeze-thaw treatments.

Pharmacokinetic properties of PDCD4-AS1

The pharmacokinetic properties of PDCD4-AS1 indicate that it has rapid clearance and high expression levels. Studies have shown that PDCD4-AS1 is rapidly cleared from the body, with an elimination half-life of less than 1 hour. In addition, the high expression level of PDCD4-AS1 indicates that it has a higher protein content and can accumulate in the body.

Pathological properties of PDCD4-AS1

The expression of PDCD4-AS1 is upregulated in various cancers, indicating that it may be closely related to cancer progression and treatment response. In addition, PDCD4-AS1 can also serve as an important component in tumor tissue and participate in the formation and maintenance of tumor tissue.

Clinical research on PDCD4-AS1

As a new biomarker, PDCD4-AS1 has great potential in clinical application in tumor patients. Currently, some studies have proven that PDCD4-AS1 can be used to predict treatment effects and disease progression in cancer patients. Future research can further explore the role of PDCD4-AS1 in tumor treatment and provide better treatment options for tumor patients.

Protein Name: PDCD4 Antisense RNA 1

The "PDCD4-AS1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PDCD4-AS1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets